XML 98 R75.htm IDEA: XBRL DOCUMENT
v3.24.1

Materials Agreements (Narrative) (Details) - USD ($) $ in Thousands |  |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
May 09, 2023 | May 06, 2019 | Jul. 17, 2023 | Feb. 17, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021
Disclosure of contingent liabilities [line items] |  |  |  |  |  |  |
Research and development |  |  |  |  | $ 7,467 | $ 10,181 | $ 10,256
Revenues net |  |  |  |  | 18,686 | 26,496 | $ 23,763
Biomedical Advanced Research And Development Authority [Member] |  |  |  |  |  |  |
Disclosure of contingent liabilities [line items] |  |  |  |  |  |  |
License costs |  |  |  |  |  | $ 165,000 |
Additional funding amount | $ 10,000 |  |  |  |  |  |
Accumulated funding |  |  |  |  | 88,282 |  |
Research and development | 110,000 |  |  |  |  |  |
NexoBrid [Member] | Biomedical Advanced Research And Development Authority [Member] |  |  |  |  |  |  |
Disclosure of contingent liabilities [line items] |  |  |  |  |  |  |
Proceeds From Procurement |  |  |  |  | 16,500 |  |
Additional funding amount |  |  |  |  | 29,000 |  |
Amount of second contract was expired |  |  |  |  | 4,368 |  |
Revenues net |  |  |  |  | 10,500 |  |
NexoBrid [Member] | Biomedical Advanced Research And Development Authority [Member] | Maximum [Member] |  |  |  |  |  |  |
Disclosure of contingent liabilities [line items] |  |  |  |  |  |  |
Proceeds From Funding |  |  |  |  | 12,000 |  |
Proceeds From Procurement | $ 65,000 |  |  |  |  |  |
License Agreement with Vericel [Member] |  |  |  |  |  |  |
Disclosure of contingent liabilities [line items] |  |  |  |  |  |  |
Upfront payment |  | $ 17,500 |  |  |  |  |
Additional upfront payment |  | 7,500 |  |  |  |  |
Revenues net |  |  |  |  | 82 |  |
License Agreement with Vericel [Member] | Maximum [Member] |  |  |  |  |  |  |
Disclosure of contingent liabilities [line items] |  |  |  |  |  |  |
Additional upfront payment |  | $ 125,000 |  |  |  |  |
Biopharmax Group Ltd. contract [Member] |  |  |  |  |  |  |
Disclosure of contingent liabilities [line items] |  |  |  |  |  |  |
Amount of invested in the project |  |  | $ 12,700 |  |  |  |
DOD and MTEC contracts [Member] |  |  |  |  |  |  |
Disclosure of contingent liabilities [line items] |  |  |  |  |  |  |
Proceeds From Funding |  |  |  | $ 2,727 |  |  |
Additional funding amount |  |  |  |  | 9,117 |  |
Proceeds From Additional Procurement |  |  |  |  | 1,190 |  |
Accumulated funding |  |  |  |  | $ 10,307 |  |

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfContingentLiabilitiesLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of expenditure directly attributable to research or development activities, recognised in profit or loss. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2023-01-01 -Paragraph 126 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_ResearchAndDevelopmentExpense
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2023-01-01 -Paragraph 28 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_a&doctype=Standard -URIDate 2023-03-23 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2023-01-01 -Paragraph 23 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_a&doctype=Standard -URIDate 2023-03-23 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2023-01-01 -Paragraph 32 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard -URIDate 2023-03-23 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 5 -IssueDate 2023-01-01 -Paragraph 33 -Subparagraph b -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard -URIDate 2023-03-23 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2023-01-01 -Paragraph 33 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33_a&doctype=Standard -URIDate 2023-03-23 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2023-01-01 -Paragraph 34 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard -URIDate 2023-03-23 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2023-01-01 -Paragraph B12 -Subparagraph b -Clause v -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B -URIDate 2023-03-23 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Name IFRS -Number 12 -IssueDate 2023-01-01 -Paragraph B10 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B -URIDate 2023-03-23 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 82 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_a&doctype=Standard -URIDate 2023-03-23 Reference 10: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 103 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard -URIDate 2023-03-23 Reference 11: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 102 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_Revenue
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of transfers under licence agreements to the entity in related party transactions. [Refer: Related parties [member]] + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 24 -IssueDate 2023-01-01 -Paragraph 21 -Subparagraph f -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_21_f&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_TransfersUnderLicenseAgreementsToEntityRelatedPartyTransactions
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition Accumulated funding. + References No definition available. + Details
Name: | mdwd_AccumulatedFunding
Namespace Prefix: | mdwd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Additional upfront payment. + References No definition available. + Details
Name: | mdwd_AdditionalUpfrontPayment
Namespace Prefix: | mdwd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Information about invested in the project. + References No definition available. + Details
Name: | mdwd_AmountOfInvestedInProject
Namespace Prefix: | mdwd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Information about second contract was expired. + References No definition available. + Details
Name: | mdwd_AmountOfSecondContractExpired
Namespace Prefix: | mdwd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Additional funding amount. + References No definition available. + Details
Name: | mdwd_ProceedsFromAdditionalFunding
Namespace Prefix: | mdwd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Additional procurement amount. + References No definition available. + Details
Name: | mdwd_ProceedsFromAdditionalProcurement
Namespace Prefix: | mdwd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Funding amount. + References No definition available. + Details
Name: | mdwd_ProceedsFromFunding
Namespace Prefix: | mdwd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Procurement amount. + References No definition available. + Details
Name: | mdwd_ProceedsFromProcurement
Namespace Prefix: | mdwd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront payment. + References No definition available. + Details
Name: | mdwd_UpfrontPayment
Namespace Prefix: | mdwd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | mdwd_AgreementAxis=mdwd_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CategoriesOfRelatedPartiesAxis=mdwd_NexoBridMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CategoriesOfRelatedPartiesAxis=mdwd_LicenseAgreementWithVericelMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CategoriesOfRelatedPartiesAxis=mdwd_TurnkeyScaleUpAgreementWithBiopharmaxGroupMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CategoriesOfRelatedPartiesAxis=mdwd_UsDepartmentOfDefenseMedicalTechnologyEnterpriseConsortiumContractMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |